NCT00186641

Brief Summary

To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
203

participants targeted

Target at P75+ for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 14, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 8, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 8, 2008

Completed
Last Updated

June 5, 2026

Status Verified

June 1, 2026

First QC Date

September 14, 2005

Last Update Submit

June 3, 2026

Conditions

Graft vs Host Disease

Keywords

chronic Graft vs Host Disease

Outcome Measures

Primary Outcomes (1)

  • Survival

Interventions

high dose chemo and auto hematopoietic cell transplantPROCEDURE

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stage II, III or IV breast cancer
  • chemosensitive
  • adequate organ function

You may not qualify if:

  • prior transplant,
  • life threatening disease
  • brain metastases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University Cancer Center

Stanford, California, 94305, United States

Location

MeSH Terms

Conditions

Graft vs Host Disease

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Immune System Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Ginna Laport, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 14, 2005

First Posted

September 16, 2005

Primary Completion

February 8, 2008

Study Completion

February 8, 2008

Last Updated

June 5, 2026

Record last verified: 2026-06

Locations

US(1)